Grupo de Splicing y Cáncer, Instituto de Biología y Genética Molecular (IBGM), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Valladolid, Sanz y Forés 3, Valladolid 47003, Spain.
Breast Cancer Res. 2012 May 25;14(3):R87. doi: 10.1186/bcr3202.
The underlying pathogenic mechanism of a large fraction of DNA variants of disease-causing genes is the disruption of the splicing process. We aimed to investigate the effect on splicing of the BRCA2 variants c.8488-1G > A (exon 20) and c.9026_9030del (exon 23), as well as 41 BRCA2 variants reported in the Breast Cancer Information Core (BIC) mutation database.
DNA variants were analyzed with the splicing prediction programs NNSPLICE and Human Splicing Finder. Functional analyses of candidate variants were performed by lymphocyte RT-PCR and/or hybrid minigene assays. Forty-one BIC variants of exons 19, 20, 23 and 24 were bioinformatically selected and generated by PCR-mutagenesis of the wild type minigenes.
Lymphocyte RT-PCR of c.8488-1G > A showed intron 19 retention and a 12-nucleotide deletion in exon 20, whereas c.9026_9030del did not show any splicing anomaly. Minigene analysis of c.8488-1G > A displayed the aforementioned aberrant isoforms but also exon 20 skipping. We further evaluated the splicing outcomes of 41 variants of four BRCA2 exons by minigene analysis. Eighteen variants presented splicing aberrations. Most variants (78.9%) disrupted the natural splice sites, whereas four altered putative enhancers/silencers and had a weak effect. Fluorescent RT-PCR of minigenes accurately detected 14 RNA isoforms generated by cryptic site usage, exon skipping and intron retention events. Fourteen variants showed total splicing disruptions and were predicted to truncate or eliminate essential domains of BRCA2.
A relevant proportion of BRCA2 variants are correlated with splicing disruptions, indicating that RNA analysis is a valuable tool to assess the pathogenicity of a particular DNA change. The minigene system is a straightforward and robust approach to detect variants with an impact on splicing and contributes to a better knowledge of this gene expression step.
致病基因的很大一部分 DNA 变异的潜在致病机制是剪接过程的破坏。我们旨在研究 BRCA2 变体 c.8488-1G > A(外显子 20)和 c.9026_9030del(外显子 23)以及乳腺癌信息核心(BIC)突变数据库中报道的 41 种 BRCA2 变体对剪接的影响。
使用 NNSPLICE 和 Human Splicing Finder 等剪接预测程序分析 DNA 变体。通过淋巴细胞 RT-PCR 和/或杂交 minigene 测定对候选变体进行功能分析。从外显子 19、20、23 和 24 的 BIC 变体中生物信息学选择并通过野生型 minigene 的 PCR 诱变生成 41 个变体。
c.8488-1G > A 的淋巴细胞 RT-PCR 显示内含子 19 保留和外显子 20 缺失 12 个核苷酸,而 c.9026_9030del 没有显示任何剪接异常。c.8488-1G > A 的 minigene 分析显示了上述异常异构体,但也显示了外显子 20 跳跃。我们进一步通过 minigene 分析评估了四个 BRCA2 外显子的 41 个变体的剪接结果。18 个变体显示剪接异常。大多数变体(78.9%)破坏了天然剪接位点,而四个改变了推定的增强子/沉默子,影响较弱。minigene 的荧光 RT-PCR 准确检测到由隐式使用、外显子跳跃和内含子保留事件产生的 14 种 RNA 异构体。14 个变体显示完全剪接破坏,预计会截断或消除 BRCA2 的必需结构域。
相当一部分 BRCA2 变体与剪接破坏相关,表明 RNA 分析是评估特定 DNA 变化致病性的有价值工具。minigene 系统是一种简单而强大的方法,可以检测对剪接有影响的变体,并有助于更好地了解该基因表达步骤。